Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist
Year: 2016
Type: article
Study design: Clinical Trial
Source: Diabetes
DOI: 10.2337/db16-0107
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novartis Pharma
OpenAlex ID: W2331274473
